Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer

Kelly E van Keulen, Maud E Jansen, Ruud W M Schrauwen, Jeroen J Kolkman, Peter D Siersema, Kelly E van Keulen, Maud E Jansen, Ruud W M Schrauwen, Jeroen J Kolkman, Peter D Siersema

Abstract

Background: Colorectal cancer (CRC) is the third most common cancer diagnosis in the Western world.

Aim: To evaluate exhaled volatile organic compounds (VOCs) as a non-invasive biomarker for the detection of CRC and precursor lesions using an electronic nose.

Methods: In this multicentre study adult colonoscopy patients, without inflammatory bowel disease or (previous) malignancy, were invited for breath analysis. Two-thirds of the breath tests were randomly assigned to develop training models which were used to predict the diagnosis of the remaining patients (external validation). In the end, all data were used to develop final-disease models to further improve the discriminatory power of the algorithms.

Results: Five hundred and eleven breath samples were collected. Sixty-four patients were excluded due to an inadequate breath test (n = 51), incomplete colonoscopy (n = 8) or colitis (n = 5). Classification was based on the most advanced lesion found; CRC (n = 70), advanced adenomas (AAs) (n = 117), non-advanced adenoma (n = 117), hyperplastic polyp (n = 15), normal colonoscopy (n = 125). Training models for CRC and AAs had an area under the curve (AUC) of 0.76 and 0.71 and blind validation resulted in an AUC of 0.74 and 0.61 respectively. Final models for CRC and AAs yielded an AUC of 0.84 (sensitivity 95% and specificity 64%) and 0.73 (sensitivity and specificity 79% and 59%) respectively.

Conclusions: This study suggests that exhaled VOCs could potentially serve as a non-invasive biomarker for the detection of CRC and AAs. Future studies including more patients could further improve the discriminatory potential of VOC analysis for the detection of (pre-)malignant colorectal lesions. (https://ichgcp.net/clinical-trials-registry/NCT03488537" title="See in ClinicalTrials.gov">NCT03488537).

© 2019 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Electronic nose used in the study; the Aeonose (The eNose Company). Patients inhale through a carbon filter to prevent the entry of nonfiltered environmental air and breathe into the device through a disposable mouthpiece while wearing a nose clip
Figure 2
Figure 2
Flowchart. AA, advanced adenoma; CRC, colorectal cancer; HP, hyperplastic polyp; N, number; NA, non‐advanced adenoma
Figure 3
Figure 3
ROC curve plus scatter plot of the final disease‐specific model for colorectal cancer (CRC). In the scatter plot the individual e‐nose value of each patient and control is plotted. Patients with histopathologically confirmed CRC are represented with a red square and all healthy controls are represented with a green dot. The blue line at −0.03 indicates the cut‐off point used in this study. All patients with a value greater than −0.03 were indicated as positive for CRC by the e‐nose

References

    1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–691.
    1. Endoscopy ASfG .Colorectal cancer statistics. (updated February 2014; cited 2018 27‐11‐2018).
    1. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017;67:177–193. 10.3322/caac.21395.
    1. Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016;11:967–976.
    1. Atkin WS, Morson BC, Cuzick J. Long‐term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med. 1992;326:658–662.
    1. Tolliver KA, Rex DK. Colonoscopic polypectomy. Gastroenterol Clin North Am. 2008;37:229–251, ix.
    1. Nakama H, Zhang B, Zhang X. Evaluation of the optimum cut‐off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer. 2001;37:398–401.
    1. Katsoula A, Paschos P, Haidich A‐B, Tsapas A, Giouleme O. Diagnostic accuracy of fecal immunochemical test in patients at increased risk for colorectal cancer: a meta‐analysis. JAMA Intern Med. 2017;177:1110.
    1. Stracci F, Zorzi M, Grazzini G. Colorectal cancer screening: tests, strategies, and perspectives. Front Public Health. 2014;2:210.
    1. Benito L, Travier N, Binefa G, et al. Longitudinal adherence to immunochemical fecal occult blood testing vs guaiac‐based FOBT in an organized colorectal cancer screening program. Cancer Prev Res. 2019;12:327–334.
    1. van der Vlugt M, Grobbee EJ, Bossuyt PMM, et al. Adherence to colorectal cancer screening: four rounds of faecal immunochemical test‐based screening. Br J Cancer. 2017;116:44–49.
    1. Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164:456–463.
    1. Osborne JM, Wilson C, Duncan A, et al. Patterns of participation over four rounds of annual fecal immunochemical test‐based screening for colorectal cancer: what predicts rescreening? BMC Public Health. 2017;18:81.
    1. Shirasu M, Touhara K. The scent of disease: volatile organic compounds of the human body related to disease and disorder. J Biochem. 2011;150:257–266.
    1. Amann A, Costello BDL, Miekisch W, et al. The human volatilome: volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva. J Breath Res. 2014;8:034001.
    1. Lewis JM, Savage RS, Beeching NJ, Beadsworth MBJ, Feasey N, Covington JA. Identifying volatile metabolite signatures for the diagnosis of bacterial respiratory tract infection using electronic nose technology: a pilot study. PLoS ONE. 2017;12:e0188879.
    1. van Oort PM, de Bruin S, Weda H, et al. Exhaled breath metabolomics for the diagnosis of pneumonia in intubated and mechanically‐ventilated intensive care unit (ICU)‐patients. Int J Mol Sci. 2017;18:449.
    1. Behera B, Joshi R, Anil Vishnu GK, Bhalerao S, Pandya HJ. Electronic nose: a non‐invasive technology for breath analysis of diabetes and lung cancer patients. J Breath Res. 2019;13:024001.
    1. Jia Z, Zhang H, Ong CN, et al. Detection of lung cancer: concomitant volatile organic compounds and metabolomic profiling of six cancer cell lines of different histological origins. ACS Omega. 2018;3:5131–5140.
    1. Phillips M, Cataneo RN, Cruz‐Ramos JA, et al. Prediction of breast cancer risk with volatile biomarkers in breath. Breast Cancer Res Treat. 2018;170:343–350.
    1. Altomare DF, Di Lena M, Porcelli F, et al. Exhaled volatile organic compounds identify patients with colorectal cancer. Brit J Surg. 2013;100:144–150.
    1. Wang C, Ke C, Wang X, et al. Noninvasive detection of colorectal cancer by analysis of exhaled breath. Anal Bioanal Chem. 2014;406:4757–4763.
    1. Peng G, Hakim M, Broza YY, et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer. 2010;103:542–551.
    1. Amal H, Leja M, Funka K, et al. Breath testing as potential colorectal cancer screening tool. Int J Cancer. 2016;138:229–236.
    1. Bond A, Greenwood R, Lewis S, et al. Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer. Aliment Pharmacol Ther. 2019;49:1005–1012.
    1. Wang X, Wang J, Rao B, Deng L. Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017;13:2848–2854.
    1. Ishibe A, Ota M, Takeshita A, et al. Detection of gas components as a novel diagnostic method for colorectal cancer. Ann Gastroenterol Surg. 2018;2:147–153.
    1. Sonoda H, Kohnoe S, Yamazato T, et al. Colorectal cancer screening with odour material by canine scent detection. Gut. 2011;60:814–819.
    1. de Meij TG, Larbi IB, van der Schee MP, et al. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study. Int J Cancer. 2014;134:1132–1138.
    1. Batty CA, Cauchi M, Lourenco C, Hunter JO, Turner C. Use of the analysis of the volatile faecal metabolome in screening for colorectal cancer. PLoS ONE. 2015;10:e0130301.
    1. Arasaradnam RP, McFarlane MJ, Ryan‐Fisher C, et al. Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis. PLoS ONE. 2014;9:e108750.
    1. Mozdiak E, Wicaksono AN, Covington JA, Arasaradnam RP. Colorectal cancer and adenoma screening using urinary volatile organic compound (VOC) detection: early results from a single‐centre bowel screening population (UK BCSP). Tech Coloproctol. 2019;4:343–351.
    1. Widlak MM, Neal M, Daulton E, et al. Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers. Colorectal Dis. 2018;20:O335–O342.
    1. Silva CL, Passos M, Camara JS. Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid‐phase microextraction in combination with gas chromatography‐mass spectrometry. Br J Cancer. 2011;105:1894–1904.
    1. Westenbrink E, Arasaradnam RP, O'Connell N, et al. Development and application of a new electronic nose instrument for the detection of colorectal cancer. Biosens Bioelectron. 2015;67:733–738.
    1. Bruins M, Gerritsen JW, van de Sande WW, van Belkum A, Bos A. Enabling a transferable calibration model for metal‐oxide type electronic noses. Sens Actuators B: Chem. 2013;188:1187–1195.
    1. Bruins M, Gerritsen JW, van de Sande WWJ, van Belkum A, Bos A. Enabling a transferable calibration model for metal‐oxide type electronic noses. Sens Actuatros. 2013;88:1187–1195.
    1. van de Goor R, van Hooren M, Dingemans AM, Kremer B, Kross K. Training and validating a portable electronic nose for lung cancer screening. J Thoracic Oncol. 2018;13:676–681.
    1. van de Goor RM, Leunis N, van Hooren MRA, et al. Feasibility of electronic nose technology for discriminating between head and neck, bladder, and colon carcinomas. Eur Arch Otorhinolaryngol. 2017;274:1053–1060.
    1. Waltman CG, Marcelissen TAT, van Roermund JGH. Exhaled‐breath testing for prostate cancer based on volatile organic compound profiling using an electronic nose device (Aeonose): a preliminary report. Eur Urol Focus. 2018. 10.1016/j.euf.2018.11.006 [Epub ahead of print]
    1. Berendsen RR, van Vessem ME, Bruins M, Teppema L, Aarts L, Kayser B. Electronic nose technology fails to sniff out acute mountain sickness. High Alt Med Biol. 2018;19:232–236.
    1. Bruins M, Rahim Z, Bos A, van de Sande WW, Endtz HP, van Belkum A. Diagnosis of active tuberculosis by e‐nose analysis of exhaled air. Tuberculosis. 2013;93:232–238.
    1. Leunis N, Boumans M‐L, Kremer B, et al. Application of an electronic nose in the diagnosis of head and neck cancer. Laryngoscope. 2014;124:1377–1381.
    1. van Hooren MR, Leunis N, Brandsma DS, Dingemans AC, Kremer B, Kross KW. Differentiating head and neck carcinoma from lung carcinoma with an electronic nose: a proof of concept study. Eur Arch Otorhinolaryngol. 2016;273:3897–3903.
    1. Chan DK, Zakko L, Visrodia KH, et al. Breath testing for Barrett's esophagus using exhaled volatile organic compound profiling with an electronic nose device. Gastroenterology. 2017;152:24–26.
    1. Kort S, Tiggeloven MM, Brusse‐Keizer M, et al. Multi‐centre prospective study on diagnosing subtypes of lung cancer by exhaled‐breath analysis. Lung Cancer. 2018;125:223–229.
    1. Bijl E, Groeneweg G, Wesselius D, Stronks D, Huygen F. Diagnosing complex regional pain syndrome using an electronic nose, a pilot study. J Breath Res. 2019;13:036004 10.1088/1752-7163/aaf9c1
    1. Kort S, Brusse‐Keizer M, Gerritsen JW, van der Palen J. Data analysis of electronic nose technology in lung cancer: generating prediction models by means of Aethena. J Breath Res. 2017;11:026006.
    1. Kroonenberg PM. Applied multiway data analysis. Hoboken, NJ: Psychometrika; 2008. ISBN: 978‐0‐470‐16479‐6.
    1. Barash O, Zhang W, Halpern JM, et al. Differentiation between genetic mutations of breast cancer by breath volatolomics. Oncotarget. 2015;6:44864–44876.
    1. Gao Q, Su X, Annabi MH, et al. Application of urinary volatile organic compounds (VOCs) for the diagnosis of prostate cancer. Clin Genitourin Canc. 2019;17:183–190.
    1. Khalid T, Aggio R, White P, et al. Urinary volatile organic compounds for the detection of prostate cancer. PLoS ONE. 2015;10:e0143283.
    1. Xu Z‐Q, Broza YY, Ionsecu R, et al. A nanomaterial‐based breath test for distinguishing gastric cancer from benign gastric conditions. Br J Cancer. 2013;108:941–950.
    1. Kumar S, Huang J, Abbassi‐Ghadi N, et al. Mass spectrometric analysis of exhaled breath for the identification of volatile organic compound biomarkers in esophageal and gastric adenocarcinoma. Ann Surg. 2015;262:981–990.
    1. Kokoszka J, Nelson RL, Swedler WI, Skosey J, Abcarian H. Determination of inflammatory bowel disease activity by breath pentane analysis. Dis Colon Rectum. 1993;36:597–601.
    1. Dryahina K, Smith D, Bortlik M, Machkova N, Lukas M, Spanel P. Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn's disease and ulcerative colitis. J Breath Res. 2017;12:016002.
    1. Ulanowska A, Kowalkowski T, Hrynkiewicz K, Jackowski M, Buszewski B. Determination of volatile organic compounds in human breath for Helicobacter pylori detection by SPME‐GC/MS. Biomed Chromatogr. 2011;25:391–397.
    1. Hryniuk A, Ross BM. A preliminary investigation of exhaled breath from patients with celiac disease using selected ion flow tube mass spectrometry. J Gastrointest Liver Dis. 2010;19:15–20.
    1. Arasaradnam RP, McFarlane M, Daulton E, et al. Non‐invasive exhaled volatile organic biomarker analysis to detect inflammatory bowel disease (IBD). Dig Liver Dis. 2016;48:148–153.
    1. Garner CE, Smith S, de Lacy Costello B, et al. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J. 2007;21:1675–1688.
    1. Probert CS, Ahmed I, Khalid T, Johnson E, Smith S, Ratcliffe N. Volatile organic compounds as diagnostic biomarkers in gastrointestinal and liver diseases. J Gastrointest Liver Dis. 2009;18:337–343.
    1. Dahmus JD, Kotler DL, Kastenberg DM, Kistler CA. The gut microbiome and colorectal cancer: a review of bacterial pathogenesis. J Gastrointest Oncol. 2018;9:769–777.
    1. Bosch S, Lemmen JPM, Menezes R, et al. The influence of lifestyle factors on fecal volatile organic compound composition as measured by an electronic nose. J Breath Res. 2019;13:046001.
    1. El Manouni El Hassani S, Niemarkt H, Said H, et al. Fecal volatile organic compounds in preterm infants are influenced by enteral feeding composition. Sensors. 2018;18:3037.
    1. Blanchet L, Smolinska A, Baranska A, et al. Factors that influence the volatile organic compound content in human breath. J Breath Res. 2017;11:016013.
    1. Baranska A, Tigchelaar E, Smolinska A, et al. Profile of volatile organic compounds in exhaled breath changes as a result of gluten‐free diet. J Breath Res. 2013;7:037104.
    1. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS ONE. 2013;8:e70803.
    1. Altomare DF, Porcelli F, Picciariello A, et al. The use of the PEN3 e‐nose in the screening of colorectal cancer and polyps. Tech Coloproctol. 2016;20:405–409.
    1. Leja M, Amal H, Lasina I, et al. Analysis of the effects of microbiome‐related confounding factors on the reproducibility of the volatolomic test. J Breath Res. 2016;10:037101.
    1. van de Goor R, Hardy JCA, van Hooren MRA, Kremer B, Kross KW. Detecting recurrent head and neck cancer using electronic nose technology: a feasibility study. Head Neck. 2019;41:2983–2990.
    1. van Geffen WH, Bruins M, Kerstjens HA. Diagnosing viral and bacterial respiratory infections in acute COPD exacerbations by an electronic nose: a pilot study. J Breath Res. 2016;10:036001.
    1. Bannier M, van de Kant KDG, Jobsis Q, Dompeling E. Feasibility and diagnostic accuracy of an electronic nose in children with asthma and cystic fibrosis. J Breath Res. 2019;13:036009.
    1. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006;101:343–350.
    1. Wilson AD. Application of electronic‐nose technologies and VOC‐biomarkers for the noninvasive early diagnosis of gastrointestinal diseases (dagger). Sensors. 2018;18:2613.
    1. Romain A‐C, Nicolas J. Long term stability of metal oxide‐based gas sensors for e‐nose environmental applications: An overview. Sensors Actuat B Chemical. 2010;146:502–506.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi